期刊
JOURNAL OF IMMUNOLOGY
卷 200, 期 2, 页码 450-458出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1701021
关键词
-
类别
资金
- Terry Fox Research Institute [1041]
- Canadian Breast Cancer Foundation
- Canadian Cancer Society
- National Sciences and Engineering Research Council
- Canadian Graduate Scholarship (Natural Sciences and Engineering Research Council of Canada)
- Highly Qualified Personnel Scholarship (Ontario Ministry of Agriculture, Food and Rural Affairs)
Oncolytic viruses (OVs) are multimodal cancer therapeutics, with one of their dominant mechanisms being in situ vaccination. There is a growing consensus that optimal cancer therapies should generate robust tumor-specific immune responses. Immunogenic cell death (ICD) is a paradigm of cellular demise culminating in the spatiotemporal release of danger-associated molecular patterns that induce potent anticancer immunity. Alongside traditional ICD inducers like anthracycline chemotherapeutics and radiation, OVs have emerged as novel members of this class of therapeutics. OVs replicate in cancers and release tumor Ags, which are perceived as dangerous because of simultaneous expression of pathogen-associated molecular patterns that activate APCs. Therefore, OVs provide the target Ags and danger signals required to induce adaptive immune responses. This review discusses why OVs are attractive candidates for generating ICD, biological barriers limiting their success in the clinic, and groundbreaking strategies to potentiate ICD and antitumor immunity with rationally designed OV-based combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据